Eli Lilly and Company (NYSE:LLY) Shares Sold by CANADA LIFE ASSURANCE Co

CANADA LIFE ASSURANCE Co decreased its position in Eli Lilly and Company (NYSE:LLY) by 4.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 753,434 shares of the company’s stock after selling 32,328 shares during the quarter. Eli Lilly and Company accounts for about 1.0% of CANADA LIFE ASSURANCE Co’s investment portfolio, making the stock its 13th largest holding. CANADA LIFE ASSURANCE Co’s holdings in Eli Lilly and Company were worth $581,799,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Ally Financial Inc. increased its position in shares of Eli Lilly and Company by 350.0% during the fourth quarter. Ally Financial Inc. now owns 9,000 shares of the company’s stock worth $6,948,000 after acquiring an additional 7,000 shares during the last quarter. Tobias Financial Advisors Inc. raised its holdings in Eli Lilly and Company by 4.1% in the fourth quarter. Tobias Financial Advisors Inc. now owns 307 shares of the company’s stock valued at $237,000 after acquiring an additional 12 shares in the last quarter. GKV Capital Management Co. Inc. acquired a new stake in Eli Lilly and Company in the fourth quarter valued at $11,937,000. First Commonwealth Financial Corp PA grew its holdings in Eli Lilly and Company by 1.8% during the 4th quarter. First Commonwealth Financial Corp PA now owns 2,093 shares of the company’s stock worth $1,616,000 after acquiring an additional 37 shares in the last quarter. Finally, Capital Square LLC increased its position in shares of Eli Lilly and Company by 0.3% in the 4th quarter. Capital Square LLC now owns 5,074 shares of the company’s stock worth $3,986,000 after purchasing an additional 14 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Down 2.9 %

Eli Lilly and Company stock opened at $734.85 on Thursday. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The firm’s fifty day simple moving average is $830.10 and its 200-day simple moving average is $820.95. The company has a market capitalization of $696.76 billion, a P/E ratio of 62.75, a P/E/G ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

LLY has been the topic of several research analyst reports. Morgan Stanley reduced their price target on shares of Eli Lilly and Company from $1,146.00 to $1,124.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 9th. Guggenheim lowered their target price on Eli Lilly and Company from $973.00 to $928.00 and set a “buy” rating for the company in a report on Monday. Citigroup reduced their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a report on Thursday, January 16th. Finally, The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and cut their price objective for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Two research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,012.00.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.